X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare IPCA Labs with Elder Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs ELDER PHARMA - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS ELDER PHARMA IPCA LABS/
ELDER PHARMA
 
P/E (TTM) x 30.2 -0.2 - View Chart
P/BV x 3.6 0.1 3,548.6% View Chart
Dividend Yield % 0.1 0.0 -  

Financials

 IPCA LABS   ELDER PHARMA
EQUITY SHARE DATA
    IPCA LABS
Mar-18
ELDER PHARMA
Jun-14
IPCA LABS/
ELDER PHARMA
5-Yr Chart
Click to enlarge
High Rs695380 183.0%   
Low Rs400188 212.8%   
Sales per share (Unadj.) Rs260.2491.2 53.0%  
Earnings per share (Unadj.) Rs19.0-3.2 -596.3%  
Cash flow per share (Unadj.) Rs33.114.4 229.4%  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs213.0376.5 56.6%  
Shares outstanding (eoy) m126.2020.54 614.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.10.6 364.1%   
Avg P/E ratio x28.9-89.3 -32.3%  
P/CF ratio (eoy) x16.619.7 84.1%  
Price / Book Value ratio x2.60.8 340.8%  
Dividend payout %5.30-   
Avg Mkt Cap Rs m69,1205,833 1,184.9%   
No. of employees `00013.3NA-   
Total wages/salary Rs m7,3592,179 337.7%   
Avg. sales/employee Rs Th2,477.4NM-  
Avg. wages/employee Rs Th555.2NM-  
Avg. net profit/employee Rs Th180.6NM-  
INCOME DATA
Net Sales Rs m32,83610,089 325.5%  
Other income Rs m418257 162.9%   
Total revenues Rs m33,25410,346 321.4%   
Gross profit Rs m4,505-792 -568.9%  
Depreciation Rs m1,777361 491.9%   
Interest Rs m2402,756 8.7%   
Profit before tax Rs m2,905-3,653 -79.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m03,713 0.0%   
Tax Rs m511125 408.4%   
Profit after tax Rs m2,394-65 -3,663.7%  
Gross profit margin %13.7-7.8 -174.8%  
Effective tax rate %17.6-3.4 -513.5%   
Net profit margin %7.3-0.6 -1,125.7%  
BALANCE SHEET DATA
Current assets Rs m19,4559,240 210.6%   
Current liabilities Rs m10,0769,998 100.8%   
Net working cap to sales %28.6-7.5 -380.3%  
Current ratio x1.90.9 208.9%  
Inventory Days Days9846 211.4%  
Debtors Days Days6760 111.7%  
Net fixed assets Rs m20,26010,124 200.1%   
Share capital Rs m252206 122.7%   
"Free" reserves Rs m26,6335,582 477.1%   
Net worth Rs m26,8867,734 347.7%   
Long term debt Rs m2,3404,889 47.9%   
Total assets Rs m41,17322,882 179.9%  
Interest coverage x13.1-0.3 -4,025.7%   
Debt to equity ratio x0.10.6 13.8%  
Sales to assets ratio x0.80.4 180.9%   
Return on assets %6.411.8 54.4%  
Return on equity %8.9-0.8 -1,053.8%  
Return on capital %10.822.3 48.2%  
Exports to sales %47.63.0 1,567.6%   
Imports to sales %14.90.4 3,481.5%   
Exports (fob) Rs m15,642307 5,101.8%   
Imports (cif) Rs m4,88443 11,330.9%   
Fx inflow Rs m15,642307 5,101.8%   
Fx outflow Rs m4,884125 3,897.5%   
Net fx Rs m10,759181 5,934.1%   
CASH FLOW
From Operations Rs m3,41111,754 29.0%  
From Investments Rs m-1,354-561 241.6%  
From Financial Activity Rs m-1,304-6,762 19.3%  
Net Cashflow Rs m7534,432 17.0%  

Share Holding

Indian Promoters % 45.9 39.6 115.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 7.5 152.0%  
FIIs % 25.3 16.8 150.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 36.1 48.2%  
Shareholders   36,892 16,479 223.9%  
Pledged promoter(s) holding % 2.1 77.6 2.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   FULFORD INDIA  SUVEN LIFE  CIPLA  WOCKHARDT LTD.  VENUS REMEDIES  

Compare IPCA LABS With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 290 Points; Realty and PSU Stocks Witness Selling(Closing)

After opening the day on a negative note, share markets in India continued their downtrend throughout the day and ended in red.

Related Views on News

IPCA LABS Announces Quarterly Results (1QFY19); Net Profit Down 423.6% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, IPCA LABS has posted a net profit of Rs 655 m (down 423.6% YoY). Sales on the other hand came in at Rs 9 bn (up 19.8% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (4QFY18); Net Profit Up 15.6% (Quarterly Result Update)

May 30, 2018 | Updated on May 30, 2018

For the quarter ended March 2018, IPCA LABS has posted a net profit of Rs 513 m (up 15.6% YoY). Sales on the other hand came in at Rs 8 bn (up 17.6% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)

Sep 6, 2018

The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?

As the Rupee Takes a Record Plunge, These Pharma Stocks Gain the Most(Sector Info)

Sep 5, 2018

Most pharma stocks were trading with gains amid rupee's fresh fall. Does that mean pharma stocks are back in vogue?

Why Arun Jaitley's Demonetisation Defence Doesn't Add Up(Vivek Kaul's Diary)

Sep 5, 2018

The tax collected has gone up a little but the question is at what cost.

The Cream of Small Cap Stocks(Profit Hunter)

Sep 5, 2018

Akin to skimming the cream off milk, one needs to learn to skim the cream off small cap stocks.

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Sep 18, 2018 03:35 PM

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS - DISHMAN PHARMA COMPARISON

COMPARE IPCA LABS WITH

MARKET STATS